Loading market dashboard
Global X China Biotech Innovation ETF
CHBFinancial ServicesNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
[url="]Ionis Pharmaceuticals, Inc.[/url] (Nasdaq: IONS) partner GSK today announced positive pivotal data for bepirovirsen, an investigational antisense oligon
Targeting New JORC Mineral Resources at 'Challenger 3' Target HIGHLIGHTS 8,065m reverse circulation (RC) Resource upgrade drilling recently completed at Challenger ‘Main', ‘Challenger West' (CW) open pits, and ‘Challenger South-Southwest' (CSSW) and ‘Challenger 3' targets1 New assays confirm CSSW and Challenger 3 mineralisation, and support a potential new Challenger 3 JORC (2012) Mineral Resource Estimate (MRE), including: Hole ID Interval Including: CHB0197 8m @ 1.68 g/t Au from 55 metres 1m @ 7.64 g/t Au from 57 metres CHB0204 6m @ 4.46 g/t Au from 30 metres 2m @ 12.1 g/t Au from 30 metres CHB0206 10m @ 1.33 g/t Au from 44 metres 1m @ 5.61 g/t Au from 46 metres CHB0213 10m @ 2.28 g/t Au from 33 metres 1m @ 9.12 g/t Au from 42 metres CHB0222 7m @ 3.28 g/t Au from 30 metres 1m @ 16.5 g/t Au from 30 metres CHB0225 2m @ 5.12 g/t Au from 30 metres 1m @ 9.17g/t Au from 31 metres CHB0236 6m @ 1.66 g/t Au from 24 metres 1m @ 6.93 g/t Au from 25 metres Recent assays have also identified new high-grade mineralisation up to 170 g/t Au in the ‘Main' open pit walls, and mineralisation up to 60 g/t Au in the Challenger West open pit floor2 Challenger DFS underway targeting a viable, simplified ‘baseline' Stage 1 operation to underwrite restart of CGM and maximise Challenger, Tarcoola, Wudinna and Tolmer development optionality ADELAIDE, AU / ACCESS Newswire / May 19, 2026 / Barton Gold Holdings Limited (ASX:BGD)(OTCQB:BGDFF)(FRA:BGD3) (Barton or Company) is pleased to announce further assay results from recent drilling at its South Australian Challenger Gold Project (Challenger). These assays come from the CSSW Deposit and ‘Challenger 3' target, both of which are potential new open pits.
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or the “Company”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United States and China, today announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for F351 (hydronidone) as a treatment for chronic hepatitis B (CHB)-induced liver fibrosis, which is liver damage resulting from the infection of the hepatitis B virus (HBV). The acceptance comes after the NMPA previously granted priority review status for F351 in March after Gyre submitted the NDA through its majority-owned subsidiary Gyre Pharmaceuticals Co., Ltd.
Shallow, high-grade mineralisation in floor of existing open pit HIGHLIGHTS 8,065m reverse circulation (RC) Resource upgrade drilling recently completed at Challenger ‘Main', ‘Challenger West' (CW) open pits, and ‘Challenger South-Southwest' (CSSW) and ‘Challenger 3' targets Recent Challenger's ‘Main' assays identified new high-grade mineralisation in open pit walls; new Challenger West assays confirm high-grade mineralisation in the pit's floor, and include: Hole ID Interval Including: CHB0149 7m @ 2.01 g/t Au from 0 metres 1m @ 9.63 g/t Au from 6 metres CHB0150 3m @ 20.6 g/t Au from 13 metres 1m @ 59.5 g/t Au from 15 metres CHB0151 1m @ 12.5 g/t Au from 28 metres CHB0152 1m @ 20.5 g/t Au from 17 metres Assays pending for CSSW and Challenger 3 targets (along strike of ‘Main' and ‘West' pits) Challenger DFS underway targeting a viable, simplified ‘baseline' Stage 1 operation to underwrite restart of CGM and maximise Challenger, Tarcoola, Wudinna and Tolmer development optionality ADELAIDE, AU / ACCESS Newswire / April 21, 2026 / Barton Gold Holdings Limited (ASX:BGD)(OTCQB:BGDFF)(FRA:BGD3) (Barton or Company) is pleased to announce further assay results from recent drilling at its South Australian Challenger Gold Project (Challenger). Challenger is the site of the Company's fully permitted Central Gawler Mill (CGM).
New zones of high-grade mineralisation identified in open pit walls HIGHLIGHTS 8,065m reverse circulation (RC) Resource upgrade drilling recently completed at Challenger 'Main', 'Challenger West' (CW) open pits, and 'Challenger South-Southwest' (CSSW) and 'Challenger 3' targets[1] Challenger's 'Main' open pit operated during 2002 - 2004; drilling has identified new high-grade mineralisation in the open pit's walls and extensions, where new assays include: [2] Hole ID Interval Including: CHB0140 9m @ 2.20 g/t Au from 97 metres 1m @ 6.63 g/t Au from 103 metres CHB0158 11m @ 5.67 g/t Au from 24 metres 10m @ 17.7 g/t Au from 40 metres 1m @ 50.9 g/t Au from 27 metres 1m @ 170.7 g/t Au from 43 metres CHB0159 14m @ 1.01 g/t Au from 19 metres 3m @ 4.72 g/t Au from 40 metres 3m @ 2.55 g/t Au from 22 metres 1m @ 11.8 g/t Au from 40 metres CHB0165 3m @ 6.85 g/t Au from 121 metres 1m @ 15.0 g/t Au from 121 metres Further assays pending for the CW open pit, and the CSSW and Challenger 3 open pit targets Challenger DFS underway targeting a viable, simplified 'baseline' Stage 1 operation to underwrite restart of CGM and maximise Challenger, Tarcoola, Wudinna and Tolmer development optionality ADELAIDE, AU / ACCESS Newswire / April 19, 2026 / Barton Gold Holdings Limited (ASX:BGD)(OTCQB:BGDFF)(FRA:BGD3) (Barton or Company) is pleased to announce initial assay results from recent drilling at its South Australian Challenger Gold Project (Challenger). Challenger is the site of the Company's fully permitted Central Gawler Mill (CGM).
SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre or Gyre Therapeutics) (Nasdaq: GYRE), a San Diego-based innovative commercial stage biopharmaceutical company with operations in the United States and China, today announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted priority review status to the New Drug Application (NDA) for Hydronidone (F351) as a treatment for chronic hepatitis B (CHB)-induced liver fibrosis, which is liver damage resulting from the infection of the hepatitis B virus (HBV). This decision by CDE was made following the pre-NDA communication meeting previously announced on January 5, 2026 and is a major milestone in the NDA process.
